J M McKenney
Overview
Explore the profile of J M McKenney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
487
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maki K, Curry L, Reeves M, Toth P, McKenney J, Farmer M, et al.
Food Chem Toxicol
. 2008 Jun;
46 Suppl 7:S47-53.
PMID: 18555575
This trial evaluated the effects of 16 weeks of consumption of 1000mg rebaudioside A (n=60) a steviol glycoside with potential use as a sweetener, compared to placebo (n=62) in men...
2.
Maki K, Curry L, Carakostas M, Tarka S, Reeves M, Farmer M, et al.
Food Chem Toxicol
. 2008 Jun;
46 Suppl 7:S40-6.
PMID: 18555574
Rebaudioside A and stevioside are steviol glycosides extracted from the plant Stevia rebaudiana Bertoni and are used in several countries as food and beverage sweeteners. This randomized, double-blind trial evaluated...
3.
McKenney J, Swearingen D, Di Spirito M, Doyle R, Pantaleon C, Kling D, et al.
J Clin Pharmacol
. 2006 Jul;
46(7):785-91.
PMID: 16809804
The coadministration of prescription omega-3-acid ethyl esters (P-OM3) with a statin may present a treatment option for patients with mixed hyperlipidemia. This open-label, randomized, 2-way crossover, drug-drug interaction study evaluated...
4.
Ashraf T, Langley P, Hay J, BONNETTE J, McKenney J
Value Health
. 2006 May;
1(4):216-7.
PMID: 16674542
No abstract available.
5.
McKenney J
Value Health
. 2006 May;
1(4):212-5.
PMID: 16674541
The current level of noncompliance with prescription medications exerts a tremendous burden on the healthcare system in terms of both cost and poor health. The process of developing a program...
6.
McKenney J
Cardiovasc Drugs Ther
. 2002 Feb;
15(5):413-22.
PMID: 11855660
Reducing elevated levels of low-density-lipoprotein cholesterol (LDL-C) significantly reduces the incidence of coronary heart disease (CHD) events and mortality in hypercholesterolemic patients. CHD risk reduction is proportional to LDL-C reduction....
7.
McKenney J
Am J Manag Care
. 2001 Aug;
7(9 Suppl):S299-306.
PMID: 11517816
The treatment of hypercholesterolemia in the United States begins with the recognition of elevated low-density lipoprotein cholesterol (LDL-C) as the primary target. An optimal LDL-C level has been defined as...
8.
McKenney J
J Am Pharm Assoc (Wash)
. 2001 Aug;
41(4):596-607.
PMID: 11486986
Objective: To summarize for pharmacists the Adult Treatment Panel III (ATP III), recently issued guidelines for managing hypercholesterolemia, from the National Cholesterol Education Program (NCEP). Data Sources: Executive summary of...
9.
McKenney J, McCormick L, Schaefer E, Black D, WATKINS M
Am J Cardiol
. 2001 Jul;
88(3):270-4.
PMID: 11472706
This study was conducted to determine the efficacy of atorvastatin and niacin on lipoprotein subfractions in patients with atherogenic dyslipidemia. This was a multicenter, randomized, open-label, parallel-design study of patients...
10.